Search

Serabelisib

of TAK-117 (MLN1117) in Healthy Participants). … Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics

Washed Microbiota Transplantation

Fecal microbiota transplantation (FMT) is effective in enhancing the gut microbiota of patients experiencing a high range of disease states, including Clostridioides difficile (C. diff) infection, Crohn … Washed microbiota preparation (WMT) involves a method wherein FMT is used, but the preparation undergoes microfiltration through an automatic purification system combined with repeated centrifugation and

Efinopegdutide

Efinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy

Giredestrant

Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive

Ramosetron

Currently, ramosetron is only approved for use Japan and in certain Southeast Asian countries. … Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions.

Valdecoxib

Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

SAR445136

HbF production in erythrocytes (RBC). … SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.

Tefidsogene civaparvovec

It consists of an adeno-associated virus (AAV) type 2/6 vector and a zinc finger nuclease (ZFN) system that inserts a correct copy of the Iduronate 2-Sulfatase (IDS) gene into the albumin locus in hepatocytes … Tefidsogene civaparvovec, formerly known as SB-913, is an investigational therapy for genome editing.

ACY001

Pelitinib

Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.